Mizuho Reiterates Buy Rating on Cytokinetics with $118 Target
Mizuho has reaffirmed its buy rating on Cytokinetics, setting a price target of $118, a 46.04% upside from the current price.
Key Points
- Mizuho reiterated a buy rating on Cytokinetics, Incorporated (CYTK) with a price target of $118 on June 24, 2026.
- Mizuho's $118 price target implies 46.04% upside from Cytokinetics, Incorporated's ($CYTK) current $80.80 share price.
- Shares of NasdaqGS:CYTK traded near $80.01 on Wednesday, with a market cap of approximately $10.75 billion.
- Notable institutional activity included T. Rowe Price reducing its stake by 192,532 shares and Vanguard Portfolio Management opening a new position.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mizuho has reiterated its buy rating on Cytokinetics, Incorporated (NasdaqGS:CYTK) with a price target of $118. This reaffirmation by analyst Salim Syed was announced on June 24, 2026. Shares of Cytokinetics traded near $80.01 on Wednesday.
Mizuho vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Cytokinetics
In recent moves within Cytokinetics' shareholder base, T. Rowe Price Investment Management reduced its holdings by 192,532 shares, bringing its total to 17,523,840 shares valued at about $1.15 billion, a 1.1% decrease. Meanwhile, BlackRock added 152,888 shares, resulting in a total of 16,548,011 shares worth approximately $1.09 billion, reflecting a 0.9% increase. FMR LLC significantly trimmed its position by 2,084,612 shares, ending with 10,723,140 shares valued at $706.76 million, marking a 16.3% decrease. Wellington Management Group slightly increased its stake by 72,426 shares to a total of 8,009,489 shares worth around $527.91 million, a 0.9% increase. Vanguard Portfolio Management LLC opened a new position with 5,843,782 shares valued at $385.16 million.
Cytokinetics, Incorporated Stock Up 12.1%
Shares of Cytokinetics traded near $80.01 on Wednesday. The company has a market capitalization of about $10.75 billion and a forward P/E ratio that is not meaningful because the company isn't currently profitable. Its beta is 0.435, indicating lower volatility compared to the broader market. The stock's 52-week range is between $31.99 and $80.80. Its 50-day moving average is $70.93, and the 200-day moving average is $63.72. The company maintains a strong liquidity position with a current ratio of 4.214 and a quick ratio of 4.144.
$CYTK price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
Cytokinetics reported revenue of $105.82 million, reflecting a growth of 11.3%. Despite this growth, the company posted a negative EPS of -$6.86, with no net margin, indicating ongoing investments in its pipeline. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Cytokinetics, Incorporated
On June 23, 2026, Malik Fady Ibrahim, EVP of Research & Development, executed multiple transactions. He sold 3,500 shares at an average price of $79.51 under a Rule 10b5-1 plan, and separately acquired 3,500 shares at $7.8 outside of a planned transaction. Earlier, on June 9, 2026, he bought 3,500 shares at $7.8 and sold the same amount at $67.98 under a planned sale. Additionally, Robert Blum, President & CEO, sold 7,500 shares at $70.46 on June 15, 2026, as part of a planned transaction.
Analysts Set New Price Targets
On June 24, 2026, Mizuho maintained its buy rating on Cytokinetics, with a price target of $118. Citigroup initiated coverage with a buy rating and a $99 target on May 19, 2026. JP Morgan maintained its buy rating with a $97 target on May 12, 2026. HC Wainwright & Co. kept its buy rating with a $140 target on May 11, 2026. Overall, the consensus among 20 analysts is a buy, with a mean target price of $104.70.
About Cytokinetics, Incorporated
Cytokinetics, Incorporated is a biopharmaceutical company based in South San Francisco, California. It focuses on discovering and developing muscle activators and inhibitors to treat various debilitating diseases. The company markets MYQORZO, a cardiac myosin inhibitor, and is developing other treatments like Aficamten and omecamtiv mecarbil for heart conditions. Cytokinetics was founded in 1997 and employs 673 people under the leadership of CEO Robert I. Blum.
Bottom Line
Mizuho's reaffirmation of a buy rating for Cytokinetics, with a price target of $118, highlights continued confidence in the company's potential. Investors keep a close watch on such ratings, as they offer insights into the company's prospects. However, it's important to remember that these analyst ratings reflect opinions at a specific point in time and may not represent future performance.
Get Cytokinetics, Incorporated alerts
New 13F filings, insider trades, and analyst moves on $CYTK, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.